Melanoma lentiginoso acral ¿Qué sabemos de uno de los melanomas mas frecuentes en Latinoamérica?

  • Alejandra Toquica Diaz Instituto Nacional de Cancerología
  • John Nova
  • Alvaro Acosta
  • Sebastian Gil
  • Luz Dary Gutierrez
Palabras clave: Melanoma lentiginoso acral, Latinoamérica, melanoma

Resumen

El melanoma es el cáncer de piel con mayor mortalidad a nivel mundial. Se han descrito 4 subtipos principales en melanoma cutáneo; melanoma de extensión superficial, melanoma nodular, melanoma lentigo maligno y melanoma lentiginoso acral. Existen diferencias raciales en la distribución y frecuencia de éstos subtipos. En caucásicos, el riesgo es mayor para melanomas en piel expuesta a radiación UV, ya sea de forma crónica o intermitente. En contraste, en asiáticos, afroaméricanos e hispanos, la tendencia es mayor en sitios anatómicos no expuestos (palmas y plantas); melanoma que se denomina lentiginoso acral. Este melanoma usualmente se diagnostica de manera tardía, en estadios avanzados y por lo tanto tiene un peor pronóstico.

Esta revisión pretende brindar una actualización de lo que hasta ahora se conoce en melanoma lentiginoso acral, describiendo principalmente la epidemiología, los factores de riesgo asociados las características genéticas y el pronóstico del melanoma lentiginoso acral.

Descargas

La descarga de datos todavía no está disponible.

Referencias

Clark WH, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29(3):705-27.

Arrington JH, Reed RJ, Ichinose H, Krementz ET. Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. Am J Surg Pathol. 1977;1(2):131-43.

Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol. 2009;145(4):427-34.

Chang JW. Acral melanoma: a unique disease in Asia. JAMA Dermatol. 2013;149(11):1272-3.

American, Society C. Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2008.

National Cancer Institute D, Surveillance Research Program, Cancer Statistics Branch. Surveillance, Epidemiology, and End Results (SEER) Program: SEER*Stat Database. . Web site. http://www.seer.cancer.gov.%C2%A0April 2019.

Clark WH, Ainsworth AM, Bernardino EA, Yang CH, Mihm CM, Reed RJ. The developmental biology of primary human malignant melanomas. Semin Oncol. 1975;2(2):83-103.

Nagore E, Pereda C, Botella-Estrada R, Requena C, Guillén C. Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility. Cancer Causes Control. 2009;20(1):115-9.

Bristow IR, Acland K. Acral lentiginous melanoma of the foot and ankle: A case series and review of the literature. J Foot Ankle Res. 2008;1(1):11.

Freiman A, Bird G, Metelitsa AI, Barankin B, Lauzon GJ. Cutaneous effects of smoking. J Cutan Med Surg. 2004;8(6):415-23.

Puig-Butillé JA, Badenas C, Ogbah Z, Carrera C, Aguilera P, Malvehy J, et al. Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma. Exp Dermatol. 2013;22(2):148-50.

Yeh I, Jorgenson E, Shen L, Xu M, North JP, Shain AH, et al. Targeted Genomic Profiling of Acral Melanoma. J Natl Cancer Inst. 2019;111(10):1068-77.

Zhang N, Wang L, Zhu GN, Sun DJ, He H, Luan Q, et al. The association between trauma and melanoma in the Chinese population: a retrospective study. J Eur Acad Dermatol Venereol. 2014;28(5):597-603.

Jung HJ, Kweon SS, Lee JB, Lee SC, Yun SJ. A clinicopathologic analysis of 177 acral melanomas in Koreans: relevance of spreading pattern and physical stress. JAMA Dermatol. 2013;149(11):1281-8.

Kaskel P, Kind P, Sander S, Peter RU, Krähn G. Trauma and melanoma formation: a true association? Br J Dermatol. 2000;143(4):749-53.

Asgari MM, Shen L, Sokil MM, Yeh I, Jorgenson E. Prognostic factors and survival in acral lentiginous melanoma. Br J Dermatol. 2017;177(2):428-35.

Lino-Silva LS, Domínguez-Rodríguez JA, Aguilar-Romero JM, Martínez-Said H, Salcedo-Hernández RA, García-Pérez L, et al. Melanoma in Mexico: Clinicopathologic Features in a Population with Predominance of Acral Lentiginous Subtype. Ann Surg Oncol. 2016;23(13):4189-94.

Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129(7):1666-74.

Guy GP, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC, et al. Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030. MMWR Morb Mortal Wkly Rep. 2015;64(21):591-6.

Lasithiotakis KG, Leiter U, Gorkievicz R, Eigentler T, Breuninger H, Metzler G, et al. The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer. 2006;107(6):1331-9.

Aitken JF, Youlden DR, Baade PD, Soyer HP, Green AC, Smithers BM. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014. Int J Cancer. 2018;142(8):1528-35.

Ward WH, Farma JM. Cutaneous Melanoma: Etiology and Therapy. 2017.

Globocan. International Agency for Research on Cancer 2018. Estimated age-standarized incidence rates (World) in 2018, melanoma of the skin, both sexes, all ages. Recuperado de: https://gco.iarc.fr/today/fact-sheets-cancers

Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365(9460):687-701.

Castaneda CA, Torres-Cabala C, Castillo M, Villegas V, Casavilca S, Cano L, et al. Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. Clin Transl Oncol. 2017;19(12):1478-88.

Vazquez VeL, Silva TB, Vieira MeA, de Oliveira AT, Lisboa MV, de Andrade DA, et al. Melanoma characteristics in Brazil: demographics, treatment, and survival analysis. BMC Res Notes. 2015;8:4.

Loria DI GlA, Latorre C. Epidemiología del melanoma cutáneo en Argentina: análisis del registro argentino de melanoma cutáneo. RAMC. 2010; 39:45

Bravo LE, García LS, Collazos P, Carrascal E, Ramírez O, Collazos T, et al. Reliable information for cancer control in Cali, Colombia. Colomb Med (Cali). 2018;49(1):23-34.

Reyes E, Uribe C, de Vries E. Population-based incidence and melanoma-specific survival of cutaneous malignant melanoma in a Colombian population 2000-2009. Int J Dermatol. 2018;57(1):21-7.

Nova-Villanueva J, Sánchez-Vanegas G, Porras de Quintana L. [Skin cancer: a Colombian reference centre's epidemiological profile 2003-2005]. Rev Salud Publica (Bogota). 2007;9(4):595-601.

Uribe P NJ, Colmenares C, Palma L. Características de melanoma cutáneo en dos instituciones en Bogotá: análisis 2012-2016. Articulo sometido a Revista Panamericana de Salud Pública.

Pozzobon F, Acosta A, Carreño A, Fierro E. Características del melanoma cutáneo primario en el Instituto Nacional de Cancerología 2006-2010. Revista Colombiana de Cancerología 2013;17(3)111-8.

Botello-Mojica H, Insuasty-Moreno A, Jaramillo-Ayerbe F. Caracterización del melanoma maligno en la Clínica de Tumores de Piel y Mucosas, Universidad de Caldas, 2005-2015. Rev Asoc Colomb Dermatol 2017. p. 276-83.

Pozzobon F, Acosta A. Epidemiological profile of primary cutaneous melanoma over a 15-year period at a private skin cancer center in ColombiaRev. Salud Pública. 20 (2): 226-231, 2018.

Phan A, Touzet S, Dalle S, Ronger-Savlé S, Balme B, Thomas L. Acral lentiginous melanoma: histopathological prognostic features of 121 cases. Br J Dermatol. 2007;157(2):311-8.

Lea AJ. Malignant melanoma of the skin: the relationship to trauma. Ann R Coll Surg Engl. 1965;37(3):169-76.

Stalkup JR, Orengo IF, Katta R. Controversies in acral lentiginous melanoma. Dermatol Surg. 2002;28(11):1051-9.

Pereda C, Traves V, Requena C, Serra-Guillén C, Llombart B, Sanmartín O, et al. Clinical presentation of acral lentiginous melanoma: a descriptive study. Actas Dermosifiliogr. 2013;104(3):220-6.

Rolón PA, Kramárová E, Rolón HI, Khlat M, Parkin DM. Plantar melanoma: a case-control study in Paraguay. Cancer Causes Control. 1997;8(6):850-6.

Duarte CA, Flórez JP, López HG, Meneses MX, de Vries E. Survival of acral lentiginous melanoma in the National Cancer Institute of Colombia. J Eur Acad Dermatol Venereol. 2017;31(3):438-42.

Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-47.

Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014;9:239-71.

Zebary A, Omholt K, Vassilaki I, Höiom V, Lindén D, Viberg L, et al. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. J Dermatol Sci. 2013;72(3):284-9.

Gutiérrez-Castañeda LD, Nova JA, Tovar-Parra JD. Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review. Melanoma Res. 2020;30(1):62-70.

Turajlic S, Furney SJ, Lambros MB, Mitsopoulos C, Kozarewa I, Geyer FC, et al. Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res. 2012;22(2):196-207.

Furney SJ, Turajlic S, Stamp G, Thomas JM, Hayes A, Strauss D, et al. The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell Melanoma Res. 2014;27(5):835-8.

Platz A, Egyhazi S, Ringborg U, Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 2008;1(4):395-405.

Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 2002;62(11):3200-6.

Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44(9):1006-14.

Chernoff KA, Bordone L, Horst B, Simon K, Twadell W, Lee K, et al. GAB2 amplifications refine molecular classification of melanoma. Clin Cancer Res. 2009;15(13):4288-91.

Vazquez VeL, Vicente AL, Carloni A, Berardinelli G, Soares P, Scapulatempo C, et al. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. Melanoma Res. 2016;26(2):93-9.

Díaz-Granados L, Velásquez M. Mutaciones de KIT, NRAS y BRAF en melanoma. Rev Asoc Colomb Dermatol2015. p. 299-307.

Sondermeijer L, Lamboo LGE, de Waal AC, Galesloot TE, Kiemeney LALM, van Rossum M, et al. Cigarette Smoking and the Risk of Cutaneous Melanoma: A Case-Control Study. Dermatology. 2020;236(3):228-36.

Gibson JAG, Dobbs TD, Griffiths R, Song J, Akbari A, Whitaker S, et al. The association of smoking and socioeconomic status on cutaneous melanoma: a population-based, data-linkage, case-control study. Br J Dermatol. 2020;182(5):1136-47.

Tejera-Vaquerizo A, Descalzo-Gallego MA, Traves V, Requena C, Bolumar I, Pla A, et al. No association between smoking and sentinel lymph node metastasis and survival in cutaneous melanoma. J Eur Acad Dermatol Venereol. 2019;33(12):2283-90.

Jones MS, Jones PC, Stern SL, Elashoff D, Hoon DSB, Thompson J, et al. The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. Ann Surg Oncol. 2017;24(8):2089-94.

Roberts AH. Subungual melanoma following a single injury. J Hand Surg Br. 1984;9(3):328-30.

Stilwell JH, Sclare G. Malignancy following a single injury to the skin. Br J Plast Surg. 1980;33(1):74-6.

Briggs JC. The role of trauma in the aetiology of malignant melanoma: a review article. Br J Plast Surg. 1984;37(4):514-6.

Rigby HS, Briggs JC. Subungual melanoma: a clinico-pathological study of 24 cases. Br J Plast Surg. 1992;45(4):275-8.

Green A, McCredie M, MacKie R, Giles G, Young P, Morton C, et al. A case-control study of melanomas of the soles and palms (Australia and Scotland). Cancer Causes Control. 1999;10(1):21-5.

Hosokawa M, Kato T, Seiji M, Abe R. Plantar malignant melanoma. Statistical and clinicopathological studies. J Dermatol. 1980;7(2):137-42.

Dwyer PK, Mackie RM, Watt DC, Aitchison TC. Plantar malignant melanoma in a white Caucasian population. Br J Dermatol. 1993;128(2):115-20.

Li Y, Chen H, Chen G, Liu J, Zhu H, Nugasur B, et al. Trauma could as a triggering factor for development of acral lentiginous melanoma: a clinicopathologic study of 56

cases. Int

J Clin Exp Pathol 2016. p. 7800-6.

Minagawa A, Omodaka T, Okuyama R. Melanomas and Mechanical Stress Points on the Plantar Surface of the Foot. N Engl J Med. 2016;374(24):2404-6.

Costello CM, Pittelkow MR, Mangold AR. Acral Melanoma and Mechanical Stress on the Plantar Surface of the Foot. N Engl J Med. 2017;377(4):395-6.

Krementz ET, Feed RJ, Coleman WP, Sutherland CM, Carter RD, Campbell M. Acral lentiginous melanoma. A clinicopathologic entity. Ann Surg. 1982;195(5):632-45.

Nakamura Y, Fujisawa Y. Diagnosis and Management of Acral Lentiginous Melanoma. Curr Treat Options Oncol. 2018;19(8):42.

Goydos JS, Shoen SL. Acral Lentiginous Melanoma. Cancer Treat Res. 2016;167:321-9.

Soon SL, Solomon AR, Papadopoulos D, Murray DR, McAlpine B, Washington CV. Acral lentiginous melanoma mimicking benign disease: the Emory experience. J Am Acad Dermatol. 2003;48(2):183-8.

Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004;292(22):2771-6.

Saida T, Miyazaki A, Oguchi S, Ishihara Y, Yamazaki Y, Murase S, et al. Significance of dermoscopic patterns in detecting malignant melanoma on acral volar skin: results of a multicenter study in Japan. Arch Dermatol. 2004;140(10):1233-8.

Criscito MC, Stein JA. Improving the diagnosis and treatment of acral melanocytic lesions. Melanoma Manag. 2017;4(2):113-23.

Takata M, Saida T. Early cancers of the skin: clinical, histopathological, and molecular characteristics. Int J Clin Oncol. 2005;10(6):391-7.

Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35(5):433-44.

Colmenares-Roldán L, Velásquez-Lopera M, Vargas-Suaza G. Acral lentiginous melanoma: a variant of malignant melanoma of special interest in Colombia. IATREIA 2008; 21(4):386-97

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-9.

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-92.

Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2011;65(5):1032-47.

Bene NI, Healy C, Coldiron BM. Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol Surg. 2008;34(5):660-4.

Schoenfeld J, Wirth P, Helm T. Mohs micrographic surgery and secondary intention healing of a plantar melanoma in-situ. Dermatol Online J. 2017;23(2):1-3.

Egger ME, McMasters KM, Callender GG, Quillo AR, Martin RC, Stromberg AJ, et al. Unique prognostic factors in acral lentiginous melanoma. Am J Surg. 2012;204(6):874-9.

Desai A, Ugorji R, Khachemoune A. Acral melanoma foot lesions. Part 2: clinical presentation, diagnosis, and management. Clin Exp Dermatol. 2018;43(2):117-23.

Amini A, Rusthoven CG, Waxweiler TV, Jones BL, Fisher CM, Karam SD, et al. Association of health insurance with outcomes in adults ages 18 to 64 years with melanoma in the United States. J Am Acad Dermatol. 2016;74(2):309-16.

Bello DM, Chou JF, Panageas KS, Brady MS, Coit DG, Carvajal RD, et al. Prognosis of acral melanoma: a series of 281 patients. Ann Surg Oncol. 2013;20(11):3618-25.

Lv J, Dai B, Kong Y, Shen X, Kong J. Acral Melanoma in Chinese: A Clinicopathological and Prognostic Study of 142 cases. Sci Rep. 2016;6:31432.

Teramoto Y, Keim U, Gesierich A, Schuler G, Fiedler E, Tüting T, et al. Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. Br J Dermatol. 2018;178(2):443-51.

Cust AE. Prognostic features for acral lentiginous melanoma. Br J Dermatol. 2018;178(2):311-2.

Publicado
2021-05-24
Cómo citar
[1]
Toquica Diaz, A., Nova, J., Acosta, A., Gil, S. y Gutierrez, L.D. 2021. Melanoma lentiginoso acral ¿Qué sabemos de uno de los melanomas mas frecuentes en Latinoamérica?. Revista Colombiana de Cancerología. 25, 3 (may 2021), 140-53.
Sección
Artículos de revisión